BACKGROUND: The currently used National Cancer Institute (NCI) adverse events criteria for mucosal barrier injury (MBI) are insufficient for use in children. We searched for objective, easily measurable indicators for MBI in children with cancer. PURPOSE: In children with acute myeloid leukemia, various MBI-related clinical and laboratory tests were investigated, reflecting clinical severity (NCI symptomatic adverse events criteria (gold standard), daily gut score (DGS)), inflammation (plasma and fecal interleukin-8 (IL-8), fecal calprotectin), enterocytic loss (plasma citrulline, ratio fecal human DNA/total DNA) and intestinal permeability (sugar absorption tests). RESULTS: Intestinal MBI as detected by the NCI adverse events criteria was found in 55% of chemotherapy cycles, correlating well with the continuous DGS (n = 55, rho = 0.581; P < 0.001). Intestinal cell loss as measured by the ratio fecal human DNA/total DNA and plasma citrulline correlated well with both NCI criteria (n = 61, rho = 0.357, P = 0.005 resp. n = 58, rho = -0.482; P < 0.001) and DGS (n = 54, rho = 0.352, P = 0.009 resp. n = 55, rho = -0.625; P < 0.001). Plasma IL-8 correlated strongly to plasma citrulline (n = 46, rho = -0.627; P < 0.001). CONCLUSIONS: MBI was reflected by parameters indicating inflammation (IL-8) and cell loss (plasma citrulline, ratio fecal human DNA/total DNA). We conclude that plasma citrulline might be a good parameter for MBI. Further studies are needed to show whether plasma citrulline can be used as a marker for MBI in future research. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: The currently used National Cancer Institute (NCI) adverse events criteria for mucosal barrier injury (MBI) are insufficient for use in children. We searched for objective, easily measurable indicators for MBI in children with cancer. PURPOSE: In children with acute myeloid leukemia, various MBI-related clinical and laboratory tests were investigated, reflecting clinical severity (NCI symptomatic adverse events criteria (gold standard), daily gut score (DGS)), inflammation (plasma and fecal interleukin-8 (IL-8), fecal calprotectin), enterocytic loss (plasma citrulline, ratio fecal human DNA/total DNA) and intestinal permeability (sugar absorption tests). RESULTS: Intestinal MBI as detected by the NCI adverse events criteria was found in 55% of chemotherapy cycles, correlating well with the continuous DGS (n = 55, rho = 0.581; P < 0.001). Intestinal cell loss as measured by the ratio fecal human DNA/total DNA and plasma citrulline correlated well with both NCI criteria (n = 61, rho = 0.357, P = 0.005 resp. n = 58, rho = -0.482; P < 0.001) and DGS (n = 54, rho = 0.352, P = 0.009 resp. n = 55, rho = -0.625; P < 0.001). Plasma IL-8 correlated strongly to plasma citrulline (n = 46, rho = -0.627; P < 0.001). CONCLUSIONS: MBI was reflected by parameters indicating inflammation (IL-8) and cell loss (plasma citrulline, ratio fecal human DNA/total DNA). We conclude that plasma citrulline might be a good parameter for MBI. Further studies are needed to show whether plasma citrulline can be used as a marker for MBI in future research. (c) 2009 Wiley-Liss, Inc.
Authors: Kerri B Gosselin; Henry A Feldman; Andrew L Sonis; Lori J Bechard; Mark D Kellogg; Kathleen Gura; Robert Venick; Catherine M Gordon; Eva C Guinan; Christopher Duggan Journal: J Pediatr Gastroenterol Nutr Date: 2014-06 Impact factor: 2.839
Authors: Melissa A Hull; Brian A Jones; David Zurakowski; Bram Raphael; Clifford Lo; Tom Jaksic; Christopher Duggan Journal: JPEN J Parenter Enteral Nutr Date: 2011-03 Impact factor: 4.016
Authors: Thomas B Elliott; Nicolaas E Deutz; Jatinder Gulani; Amory Koch; Cara H Olsen; Christine Christensen; Mark Chappell; Mark H Whitnall; Maria Moroni Journal: Comp Med Date: 2014-12 Impact factor: 0.982
Authors: Margot Fijlstra; Edmond H H M Rings; Theo H van Dijk; Torsten Plösch; Henkjan J Verkade; Wim J E Tissing Journal: Support Care Cancer Date: 2012-09-26 Impact factor: 3.603
Authors: Margot Fijlstra; Mithila Ferdous; Anne M Koning; Edmond H H M Rings; Hermie J M Harmsen; Wim J E Tissing Journal: Support Care Cancer Date: 2014-11-08 Impact factor: 3.603
Authors: K Ryan Wessells; Sonja Y Hess; Noel Rouamba; Zinewendé P Ouédraogo; Mark Kellogg; Rie Goto; Christopher Duggan; Jean-Bosco Ouédraogo; Kenneth H Brown Journal: J Pediatr Gastroenterol Nutr Date: 2013-09 Impact factor: 2.839
Authors: Andrea M Stringer; Noor Al-Dasooqi; Joanne M Bowen; Thean H Tan; Maryam Radzuan; Richard M Logan; Bronwen Mayo; Dorothy M K Keefe; Rachel J Gibson Journal: Support Care Cancer Date: 2013-02-10 Impact factor: 3.603